Recombinant protein vaccines, a proven approach against coronavirus pandemics

J Pollet, WH Chen, U Strych - Advanced drug delivery reviews, 2021 - Elsevier
With the COVID-19 pandemic now ongoing for close to a year, people all over the world are
still waiting for a vaccine to become available. The initial focus of accelerated global …

[PDF][PDF] Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity

CX Chan, YO Yang, GHM Cheng, SK Gera… - Immune …, 2019 - synapse.koreamed.org
Background Prophylactic pinning of the uninvolved side after unilateral slipped capital
femoral epiphysis (SCFE) is controversial. The alpha angle, a measurement of femoral head …

Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine

KJ Hager, G Pérez Marc, P Gobeil… - New England journal …, 2022 - Mass Medical Soc
Abstract Background Coronavirus-like particles (CoVLP) that are produced in plants and
display the prefusion spike glycoprotein of the original strain of severe acute respiratory …

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

BJ Ward, P Gobeil, A Séguin, J Atkins, I Boulay… - Nature medicine, 2021 - nature.com
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being
deployed, but the global need greatly exceeds the supply, and different formulations might …

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

PS Arunachalam, AC Walls, N Golden, C Atyeo… - Nature, 2021 - nature.com
The development of a portfolio of COVID-19 vaccines to vaccinate the global population
remains an urgent public health imperative. Here we demonstrate the capacity of a subunit …

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind …

P Richmond, L Hatchuel, M Dong, B Ma, B Hu… - The lancet, 2021 - thelancet.com
Background As part of the accelerated development of vaccines against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant …

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

R Nachbagauer, J Feser, A Naficy, DI Bernstein… - Nature medicine, 2021 - nature.com
Seasonal influenza viruses constantly change through antigenic drift and the emergence of
pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza …

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer …

JY Song, WS Choi, JY Heo, JS Lee, DS Jung… - …, 2022 - thelancet.com
Background Vaccination has helped to mitigate the COVID-19 pandemic. Ten traditional and
novel vaccines have been listed by the World Health Organization for emergency use …

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …

PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …

“World in motion”–emulsion adjuvants rising to meet the pandemic challenges

DT O'Hagan, R van der Most, RN Lodaya, M Coccia… - npj Vaccines, 2021 - nature.com
Emulsion adjuvants such as MF59 and AS03 have been used for more than two decades as
key components of licensed vaccines, with over 100 million doses administered to diverse …